Cargando…

PRE-VACCINE COUNSELING TO ASSIST WITH RISK ASSESSMENT PRIOR TO COVID-19 VACCINATION

INTRODUCTION: During early vaccine roll-out of Pfizer-BioNTech, Moderna, and Johnson & Johnson (J&J) COVID-19 vaccines, reports of severe allergic reactions led to hesitancy among patients with allergic history and disorders. Evaluation was initially limited due to restricted access to vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblum, J., Yie, C., Akerman, M., Banta, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646433/
http://dx.doi.org/10.1016/j.anai.2022.08.556
_version_ 1784827165843390464
author Rosenblum, J.
Yie, C.
Akerman, M.
Banta, E.
author_facet Rosenblum, J.
Yie, C.
Akerman, M.
Banta, E.
author_sort Rosenblum, J.
collection PubMed
description INTRODUCTION: During early vaccine roll-out of Pfizer-BioNTech, Moderna, and Johnson & Johnson (J&J) COVID-19 vaccines, reports of severe allergic reactions led to hesitancy among patients with allergic history and disorders. Evaluation was initially limited due to restricted access to vaccines and pandemic-associated clinical constraints. METHODS: We conducted a retrospective chart review of patients over 18 years of age who sought vaccine counseling in-person or by telehealth between December 1, 2020 and May 1, 2021 prior to their first dose of vaccine. Demographics, atopic history, anaphylaxis history and vaccine administration/reactions were recorded. Follow up phone calls were used to complete data collection. RESULTS: We identified 80 patients (N= 63 Female, 17 Male). The most frequently reported comorbidities included rhinitis (54%), asthma (36%), hypertension (21%), and chronic urticaria (21%). Twenty-six patients (33%) reported a history of anaphylaxis, 14 of which were attributed to medications. Of the 80 patients evaluated, 77 (93%) successfully completed a vaccination series (defined as 1 dose of J&J or 2 doses of an mRNA vaccine). Of the 77 patients that completed vaccination, 7 (9%) reported reaction to a dose of vaccine, all consistent with expected adverse effects. No reactions suggested anaphylaxis. Three patients elected not to receive vaccination; none of these patients had history of anaphylaxis. CONCLUSION: Many patients with atopic history expressed hesitancy regarding COVID-19 vaccine administration and sought pre-vaccine counseling. Our experience suggests an effective role for counseling in patients with no prior exposure to COVID-19 vaccination as over 90% of patients with allergic history, including anaphylaxis, were safely vaccinated.
format Online
Article
Text
id pubmed-9646433
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-96464332022-11-14 PRE-VACCINE COUNSELING TO ASSIST WITH RISK ASSESSMENT PRIOR TO COVID-19 VACCINATION Rosenblum, J. Yie, C. Akerman, M. Banta, E. Ann Allergy Asthma Immunol P015 INTRODUCTION: During early vaccine roll-out of Pfizer-BioNTech, Moderna, and Johnson & Johnson (J&J) COVID-19 vaccines, reports of severe allergic reactions led to hesitancy among patients with allergic history and disorders. Evaluation was initially limited due to restricted access to vaccines and pandemic-associated clinical constraints. METHODS: We conducted a retrospective chart review of patients over 18 years of age who sought vaccine counseling in-person or by telehealth between December 1, 2020 and May 1, 2021 prior to their first dose of vaccine. Demographics, atopic history, anaphylaxis history and vaccine administration/reactions were recorded. Follow up phone calls were used to complete data collection. RESULTS: We identified 80 patients (N= 63 Female, 17 Male). The most frequently reported comorbidities included rhinitis (54%), asthma (36%), hypertension (21%), and chronic urticaria (21%). Twenty-six patients (33%) reported a history of anaphylaxis, 14 of which were attributed to medications. Of the 80 patients evaluated, 77 (93%) successfully completed a vaccination series (defined as 1 dose of J&J or 2 doses of an mRNA vaccine). Of the 77 patients that completed vaccination, 7 (9%) reported reaction to a dose of vaccine, all consistent with expected adverse effects. No reactions suggested anaphylaxis. Three patients elected not to receive vaccination; none of these patients had history of anaphylaxis. CONCLUSION: Many patients with atopic history expressed hesitancy regarding COVID-19 vaccine administration and sought pre-vaccine counseling. Our experience suggests an effective role for counseling in patients with no prior exposure to COVID-19 vaccination as over 90% of patients with allergic history, including anaphylaxis, were safely vaccinated. Published by Elsevier Inc. 2022-11 2022-11-10 /pmc/articles/PMC9646433/ http://dx.doi.org/10.1016/j.anai.2022.08.556 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle P015
Rosenblum, J.
Yie, C.
Akerman, M.
Banta, E.
PRE-VACCINE COUNSELING TO ASSIST WITH RISK ASSESSMENT PRIOR TO COVID-19 VACCINATION
title PRE-VACCINE COUNSELING TO ASSIST WITH RISK ASSESSMENT PRIOR TO COVID-19 VACCINATION
title_full PRE-VACCINE COUNSELING TO ASSIST WITH RISK ASSESSMENT PRIOR TO COVID-19 VACCINATION
title_fullStr PRE-VACCINE COUNSELING TO ASSIST WITH RISK ASSESSMENT PRIOR TO COVID-19 VACCINATION
title_full_unstemmed PRE-VACCINE COUNSELING TO ASSIST WITH RISK ASSESSMENT PRIOR TO COVID-19 VACCINATION
title_short PRE-VACCINE COUNSELING TO ASSIST WITH RISK ASSESSMENT PRIOR TO COVID-19 VACCINATION
title_sort pre-vaccine counseling to assist with risk assessment prior to covid-19 vaccination
topic P015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646433/
http://dx.doi.org/10.1016/j.anai.2022.08.556
work_keys_str_mv AT rosenblumj prevaccinecounselingtoassistwithriskassessmentpriortocovid19vaccination
AT yiec prevaccinecounselingtoassistwithriskassessmentpriortocovid19vaccination
AT akermanm prevaccinecounselingtoassistwithriskassessmentpriortocovid19vaccination
AT bantae prevaccinecounselingtoassistwithriskassessmentpriortocovid19vaccination